{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Rectal+Cancer", "query": { "condition": "Advanced Rectal Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 795, "total_pages": 80, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Rectal+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T20:17:27.291Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03037385", "title": "Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "RET-altered Non Small Cell Lung Cancer", "Medullary Thyroid Cancer", "RET-altered Papillary Thyroid Cancer", "RET-altered Colon Cancer", "RET-altered Solid Tumors", "Lung Neoplasm", "Carcinoma, Non-Small-Cell Lung", "Thyroid Diseases", "Thyroid Neoplasm", "Thyroid Cancer, Papillary", "Carcinoma, Neuroendocrine", "Respiratory Tract Neoplasms", "Thoracic Neoplasms", "Neoplasms by Site", "Neoplasms", "Lung Diseases", "Respiratory Tract Disease", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Endocrine System Diseases", "Endocrine Gland Neoplasm", "Head and Neck Neoplasms", "Adenocarcinoma, Papillary", "Adenocarcinoma", "Carcinoma", "Neoplasms, Glandular and Epithelial", "Neoplasms by Histologic Type", "Neuroendocrine Tumors", "Neuroectodermal Tumors", "Neoplasms, Germ Cell and Embryonal", "Neoplasms, Nerve Tissue", "Colonic Neoplasms", "Colorectal Neoplasms", "Intestinal Neoplasms", "Gastrointestinal Neoplasms", "Digestive System Neoplasm", "Digestive System Disease", "Gastrointestinal Disease", "Colonic Diseases", "Intestinal Disease" ], "interventions": [ { "name": "pralsetinib (BLU-667)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2017-03-17", "completion_date": "2024-03-21", "has_results": true, "last_update_posted_date": "2025-05-31", "last_synced_at": "2026-09-02T20:17:27.291Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Orange, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03037385" }, { "nct_id": "NCT01167725", "title": "Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "FOLFIRI regimen", "type": "DRUG" }, { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "mitomycin C", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 340, "start_date": "2010-08", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-09-02T20:17:27.291Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Winston-Salem, North Carolina", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01167725" }, { "nct_id": "NCT00538850", "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Fentanyl sublingual spray", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2007-10", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2014-03-05", "last_synced_at": "2026-09-02T20:17:27.291Z", "location_count": 1, "location_summary": "Chandler, Arizona", "locations": [ { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538850" }, { "nct_id": "NCT02132858", "title": "Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Mucinous Adenocarcinoma of the Rectum", "Recurrent Rectal Cancer", "Signet Ring Adenocarcinoma of the Rectum", "Stage IIA Rectal Cancer", "Stage IIB Rectal Cancer", "Stage IIC Rectal Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Rectal Cancer" ], "interventions": [ { "name": "cytology specimen collection procedure", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2014-07", "completion_date": "2022-10", "has_results": false, "last_update_posted_date": "2024-05-02", "last_synced_at": "2026-09-02T20:17:27.291Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02132858" }, { "nct_id": "NCT00052585", "title": "Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Colon", "Adenocarcinoma of the Rectum", "Mucinous Adenocarcinoma of the Colon", "Mucinous Adenocarcinoma of the Rectum", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Signet Ring Adenocarcinoma of the Colon", "Signet Ring Adenocarcinoma of the Rectum", "Stage IV Colon Cancer", "Stage IV Rectal Cancer" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "gefitinib", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2002-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-09-02T20:17:27.291Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00052585" }, { "nct_id": "NCT05565417", "title": "Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Triple Negative Breast Cancer", "Cutaneous Squamous Cell Carcinoma", "Hormone Receptor Positive Breast Carcinoma", "Small Bowel Cancer", "Esophageal Cancer", "Colorectal Cancer", "Diffuse Large B Cell Lymphoma", "Hodgkin Lymphoma", "Burkitt Lymphoma", "Follicular Lymphoma" ], "interventions": [ { "name": "IMT-009", "type": "DRUG" }, { "name": "Fruquintinib", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Immunitas Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2022-11-28", "completion_date": "2026-01", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-09-02T20:17:27.291Z", "location_count": 9, "location_summary": "Tucson, Arizona • Denver, Colorado • Orlando, Florida + 6 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05565417" }, { "nct_id": "NCT05838391", "title": "Adaptive Radiation in Anal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery", "type": "RADIATION" }, { "name": "Mitomycin-C", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-05-18", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-09-02T20:17:27.291Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05838391" }, { "nct_id": "NCT03190174", "title": "Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ewing Sarcoma", "PEComa", "Epithelioid Sarcoma", "Desmoid Tumor", "Chordoma", "Non Small Cell Lung Cancer", "Urothelial Carcinoma", "Melanoma", "Renal Cell Carcinoma", "Squamous Cell Carcinoma", "Hepatocellular Carcinoma", "Classical Hodgkin Lymphoma", "Colorectal Cancer", "MTOR Activating Mutation" ], "interventions": [ { "name": "Nab-Rapamycin", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sarcoma Oncology Research Center, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 34, "start_date": "2017-08-24", "completion_date": "2021-12-02", "has_results": true, "last_update_posted_date": "2025-02-17", "last_synced_at": "2026-09-02T20:17:27.291Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03190174" }, { "nct_id": "NCT07189871", "title": "177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Cancer (CRPC)", "Colorectal Cancer", "NSCLC (Non-small Cell Lung Cancer)", "Ovarian Cancer", "Cervical Cancer", "Endometrial Cancer", "TNBC, Triple Negative Breast Cancer", "Small Cell Lung Cancer (SCLC )", "Head &Amp; Neck Squamous Cell Carcinoma (HNSCC)", "Esophageal Squamous Cell Carcinoma (ESCC)" ], "interventions": [ { "name": "177Lu-BetaBart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Radiopharm Theranostics, Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2026-02-23", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-02T20:17:27.291Z", "location_count": 4, "location_summary": "Dothan, Alabama • Grand Rapids, Michigan • Omaha, Nebraska", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT07189871" }, { "nct_id": "NCT03300544", "title": "Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Rectal Adenocarcinoma", "Metastatic Rectal Adenocarcinoma", "Rectal Adenocarcinoma", "Stage III Rectal Cancer AJCC v7", "Stage IIIA Rectal Cancer AJCC v7", "Stage IIIB Rectal Cancer AJCC v7", "Stage IIIC Rectal Cancer AJCC v7", "Stage IV Rectal Cancer AJCC v7", "Stage IVA Rectal Cancer AJCC v7", "Stage IVB Rectal Cancer AJCC v7" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Talimogene Laherparepvec", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2019-05-14", "completion_date": "2022-03-22", "has_results": true, "last_update_posted_date": "2024-05-23", "last_synced_at": "2026-09-02T20:17:27.291Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03300544" } ] }